Applying ICIs, especially monoclonal antibodies targeting PD-1, PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and modulating immune checkpoints on tumor cells, bring significant breakthroughs in treating solid tumors, including HCC [29, 30]. Here, CTLA4 is linked to neoplasm.